Less Ads, More Data, More Tools Register for FREE

Pin to quick picksBunzl Regulatory News (BNZL)

Share Price Information for Bunzl (BNZL)

Share Price is delayed by 15 minutes
Get Live Data
2,428.00    38.00 (1.59%)
Bid:
2,428.00
Ask:
2,430.00
Spread: 2.00 (0.082%)
Market Cap: £7.80b
BNZL Live PriceLast checked at - London Stock Exchange

Intraday Bunzl Share Chart

Trading Statement

21 Apr 2021 07:00

RNS Number : 0754W
Bunzl PLC
21 April 2021
 

21 April 2021

 

BUNZL Q1 TRADING STATEMENT

 

Bunzl plc, the specialist international distribution and services Group, today announces its trading statement for the period since 31 December 2020.

 

Bunzl's diversified and resilient business model has delivered good overall growth against continuing pandemic-related challenges, with Group revenue in the first quarter up 5.4% at actual exchange rates and 10.4% at constant exchange rates. Acquisitions contributed revenue growth of 4.3% at constant exchange rates, while a greater number of trading days than the comparable period in 2020 further benefited revenue growth by 4.7%. Underlying revenue growth at constant exchange rates increased by 1.4%, in line with the Group's expectations. Group adjusted operating margin continued to be supported by demand for certain Covid-19 related products.

 

Within underlying revenue growth of 1.4%, sales of the top 8 Covid-19 related products, which are primarily own brand, contributed 6.4% of growth. This growth more than offset a 5.0% decline in revenue from other product sales. Good underlying revenue performance in North America and Rest of the World was driven by demand for Covid-19 related products, with certain category-specific pricing remaining elevated, and a continuation of the recovery in sales of other products. Continental Europe and UK & Ireland continued to be impacted by the effect of pandemic-related restrictions, particularly on foodservice and non-food retail segments.

 

The Group's guidance remains unchanged. At constant exchange rates, the Group continues to expect robust revenue growth in 2021 compared to the prior year, after excluding larger Covid-19 related orders which contributed approximately £550 million of revenue in 2020. A recovery in sales of other products is expected to be largely offset by a decline in smaller Covid-19 related orders, while recent acquisitions will further contribute to the Group's performance in 2021. After excluding larger Covid-19 related orders, the Group continues to expect good organic revenue growth in the first half of 2021 to be followed by a moderate decline in the second half. Group adjusted operating margin for the year is expected to return to a more historical level.

 

Commenting on today's results, Frank van Zanten, Chief Executive Officer of Bunzl, said:

 

"Now over a year on from the start of the pandemic I continue to thank our colleagues for their exceptional hard work supporting front line heroes and essential businesses through these extraordinary times. As activity starts to resume in some of our markets, it is with pride that I now see our teams increasingly supporting customers to reopen their businesses, many of which have been meaningfully impacted over the course of the pandemic. The resilience of the Bunzl model continues to be demonstrated by our ability to respond to changing customer needs and through our financial performance.

 

Looking ahead we are confident in the strength of our consistent and proven compounding strategy, supported by enhanced hygiene trends, our differentiated offering of sustainable and responsible solutions and acquisition momentum. We have announced three acquisitions in the year to date with the pipeline remaining active and a number of discussions ongoing."

 

Enquiries:

 

Bunzl plc

Frank van Zanten, Chief Executive Officer

Richard Howes, Chief Financial Officer

Tel: +44 (0)20 7725 5000

Tulchan

David Allchurch

Martin Robinson

Tel: +44 (0)20 7353 4200

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
TSTBSGDSCUDDGBG
Date   Source Headline
3rd Jan 202311:43 amRNSTotal Voting Rights
21st Dec 20227:00 amRNSTrading Statement
20th Dec 20227:00 amRNSAcquisition
14th Dec 20228:00 amRNSAdditional Listing
8th Dec 202212:56 pmRNSHolding(s) in Company
5th Dec 20229:45 amRNSDirector/PDMR Shareholding
1st Dec 20222:34 pmRNSTotal Voting Rights
29th Nov 20223:21 pmRNSDirector/PDMR Shareholding
11th Nov 20229:00 amRNSPublication of Admission Particulars
4th Nov 202212:08 pmRNSDirector/PDMR Shareholding
2nd Nov 20224:20 pmRNSDirector/PDMR Shareholding
1st Nov 20223:00 pmRNSTotal Voting Rights
1st Nov 202210:00 amRNSBlock listing Interim Review
20th Oct 20227:00 amRNSTrading Statement
11th Oct 20227:00 amRNSInvestor event
7th Oct 20224:11 pmRNSDirector/PDMR Shareholding
4th Oct 20224:54 pmRNSDirector/PDMR Shareholding
3rd Oct 20223:13 pmRNSTotal Voting Rights
20th Sep 20227:00 amRNSHolding(s) in Company
7th Sep 202210:59 amRNSDirector/PDMR Shareholding
1st Sep 202211:08 amRNSTotal Voting Rights
31st Aug 20221:46 pmRNSDirector/PDMR Shareholding
30th Aug 202210:00 amRNSDividend Declaration
30th Aug 20227:00 amRNSHalf-year Report
4th Aug 20229:19 amRNSDirector/PDMR Shareholding
2nd Aug 20227:00 amRNSAcquisition
1st Aug 20223:07 pmRNSTotal Voting Rights
1st Aug 202210:00 amRNSDirector Declaration
29th Jul 20227:00 amRNSAppointment of Joint Corporate Broker
19th Jul 20227:00 amRNSDirectorate Change
12th Jul 202210:32 amRNSDirector/PDMR Shareholding
6th Jul 20225:12 pmRNSDirector/PDMR Shareholding
1st Jul 20222:18 pmRNSTotal Voting Rights
30th Jun 20227:00 amRNSTrading Statement
14th Jun 20227:00 amRNSAcquisition
8th Jun 202212:44 pmRNSDirector/PDMR Shareholding
1st Jun 202210:42 amRNSTotal Voting Rights
11th May 20228:00 amRNSAdditional Listing
5th May 202211:00 amRNSDirector/PDMR Shareholding
3rd May 202211:00 amRNSTotal Voting Rights
3rd May 202210:00 amRNSBlock listing Interim Review
28th Apr 20228:00 amRNSAdditional Listing
20th Apr 20225:17 pmRNSResult of AGM
20th Apr 20227:00 amRNSTrading Statement
19th Apr 20224:59 pmRNSDirector/PDMR Shareholding
8th Apr 20225:37 pmRNSDirector/PDMR Shareholding
8th Apr 20225:36 pmRNSDirector/PDMR Shareholding
7th Apr 20222:45 pmRNSDirector/PDMR Shareholding
5th Apr 20224:03 pmRNSDirector/PDMR Shareholding
1st Apr 20223:52 pmRNSDirector/PDMR Shareholding

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.